BEAM: Brain-Eye Amyloid Memory Study
BEAM: Brain-Eye Amyloid Memory Study
The main objectives for this study are:

 1. To investigate novel, non-invasive ocular measurements including optical coherence
 tomography and eye tracking in a cross-sectional study of participants with various
 neurodegenerative dementias against standard cognitive assessments and brain imaging
 measures; and

 2. To assess the potential utility of ocular assessments for early detection in the
 pre-dementia, i.e. the so-called Mild Cognitive Impairment (MCI) stage, across the
 common neurodegenerative dementia syndromes and, Vascular Cognitive Impairment (VCI) due
 to small vessel disease (SVD).

 3. To determine the prevalence and relevance of amyloid uptake on PET scanning across the
 dementias most commonly associated with amyloidosis. Specifically we aim to examine
 correlations with amyloid uptake status in patients symptomatic from the most common
 proteinopathies (ie amyloid, tau, synuclein) combined in varying degrees with the most
 common vasculopathies (ie small vessel disease) using multimodal structural and
 functional imaging, cognitive behavioral, and gait and balance measures, taking into
 account genetic risk markers (particularly apolipoprotein E genotypes) and fluid
 biomarkers ( eg cytokines, oxidative stress, lipidomics).
1. Retinal correlations with neurodegeneration:

 1. Retinal nerve fiber layer (RNFL) pattern will differ in participants in the MCI and
 early stages of LBD spectrum, AD, and VCI, relative to normal elders. i) RNFL
 thinning around the optic disc and macular thinning will correlate with hippocampal
 atrophy and with the cortical thickness signature of MCI and AD2-4. ii) If detected
 in the other disorders, RNFL thinning will also correlate with this topographical
 AD pattern of atrophy in those who are amyloid positive on PET. iii) Retinal and
 cortical thinning will predict brain amyloid PET. iv) Selective peripapillary RNFL
 thinning in the superior and inferior quadrants described in MCI/milder AD cases
 will correlate with precuneus and lingual gyrus cortical thinning respectively.

 2. Retinal artery narrowing will correlate with presence of covert lacunar infarcts
 and retinal venular widening with moderate to severe periventricular white matter
 hyperintensities.

 2. Amyloid deposition above accepted cut-offs will vary across the 4 cohorts and when
 present will correlate meaningfully with cognitive and behavioural patterns, including
 ocular (retinal and eye tracking), gait and balance measures and brain imaging results.

 Specific hypotheses are:

 1. Apoelipoprotein E e4 carrier status will increase likelihood of amyloid positivity
 across the cohorts.

 2. Amyloid positivity will be associated with poorer short term memory performance, smaller
 hippocampal volumes, greater cortical thinning in signature areas traditionally
 associated with Alzheimer's disease, and also with lobar microbleed counts.

 3. Small Vessel Disease burden as quantified on PD/T2 and FLAIR MRI will be associated with
 speed of processing, attention and executive functions and with a different pattern of
 cortical thinning involving more inferior and medial frontal regions.

 4. Amyloid deposition as measured by regional standardized uptake value ratio (SUVR), and
 Small Vessel Disease burden will correlate differentially with structural imaging
 measures, as well as both functional and structural brain connectivity measures.

 Study Procedures Overview The study procedures are listed below in the recommended order of
 assessment but may be performed in any sequence (with specific exceptions as described).
 Multiple assessments may be performed on the same day for participant convenience. Brain
 imaging and neuropsychology procedures should be completed within 4 months of screening.

 Screening Visit Consent. The study will be explained and written informed consent for
 participation will be obtained from the patient or his/her substitute decision maker and the
 participant's study partner (if applicable).

 Screening. The general and disease-specific inclusion and exclusion criteria will be
 assessed. If the MMSE, MoCA, DOC (Depression, Obstructive Sleep Apnea, Cognition)
 questionnaire and/or TorCA (formally known as Behavioural Neurology Assessment - Revised
 (BNA-R) have not been administered within the past four months, they will be administered at
 the screening visit. Information on the patient's concomitant medications, medical, surgical,
 ophthalmological history, family health history and other relevant history will be collected,
 as well as information on both the patient's and the study partner's demographics. The
 patient's corrected near visual acuity will be checked. Auditory acuity at various
 frequencies will be assessed using an audiometer. Fasting blood will be drawn, for analysis
 of HbA1c, CBC, electrolytes, creatinine, urea, lipid profile, glucose, liver function (AST,
 ALT, ALP, bilirubin), homocysteine, B12 and TSH. Blood will also be drawn for genomics and
 fluid biomarkers (see next section.)

 Genomics and Fluid Biomarkers. Fasting blood samples for genetic testing including
 apoliprotein E4 status, as well as for proteomic, lipidomic and other fluid biomarkers of
 neurodegeneration and vascular disease, will be collected from each participant.

 Neuropsychological Battery and Questionnaires. The cognitive battery comprises most of the
 tests used in the Ontario Neurodegenerative Disease Research Initiative (ONDRI) study, a new
 province-wide neurodegeneration research collaboration, with some modifications. It includes
 measures of executive function, memory, language, and visuospatial ability. Function, mood
 and behaviour, and caregiver burden will also be assessed using the questionnaires used in
 ONDRI. The full list of the assessment procedures is included in the BEAM neuropsychology
 manuals.

 SD-OCT. Assessments to meet ocular criteria will include visual acuity, intra-ocular pressure
 (IOP) measurement and a non-mydriatic fundus camera recording, performed by a certified
 ophthalmic technician. The participant will then undergo SD-OCT to determine retinal nerve
 fiber layer thickness.

 Vital Signs and Neurological Exam. Vital signs will be measured and a neurological
 examination will be performed.

 Gait and Balance Assessment. Information on aid use and balance will be collected using
 questionnaires. Participants' leg length, calf circumference, height, and weight will be
 measured and recorded when possible.

 Eye Tracking. Participants will be asked to look at a computer monitor and perform three sets
 of tasks (pro-saccade, anti-saccade, and dynamic free viewing) while a specialized camera
 tracks and records their eye movements. Participants who are unable to complete these
 assessments will be allowed to continue participation in the study.

 SV-OCT at Sunnybrook. SV-OCT will be done in subsamples with high SVD vs. minimal SVD loads.
 A rapid (>100 fps) 3D scanning protocol will be applied to SD-OCT, allowing acquisition of
 speckle variance due to microscopic blood flow in the retinal vasculature. Image processing
 using GPU based technique will provide real-time assessment of microvasculature morphology.

 MRI. 3DT1 SPGR, interleaved spin echo PD/T2 and FLAIR to assess SVD, and gradient echo images
 to assess microbleeds, will be obtained on the 3 Tesla scanners at each of the TDRA sites.
 The PD/T2 and FLAIR images are co-registered to the T1-weighted image to remove non-brain
 tissues to determine total supratentorial intracranial volume to correct for head size,
 classify brain tissue compartments and automatically identify subcortical and white matter
 hyperintensities using a published in-house pipeline, "Lesion Explorer", which with manual
 editing yields number, size, location, and volume of the hyperintensities. For hippocampal
 volume, we use our fully automated segmentation pipeline based on a template library
 registration117, 118. We will also acquire DTI to generate total and regional fractional
 anisotropy (FA) and Mean Diffusivity Maps, using FSL and DTI tool box, and a resting state
 fMRI to explore Default Mode Network (DMN) connectivity, using a processing pipeline steps
 previously applied to AD patients and controls119.

 Arterial Spin Labeling (ASL) will be included at certain sites which are capable of acquiring
 this sequence, to obtain measures of regional cerebral perfusion.

 Amyloid PET. PIB, labelled with the positron emitting atom carbon-11, is a radiotracer that
 targets Aβ-aggregates (β-amyloid) in vivo. β-amyloid deposits are present in the brain of
 patients with Alzheimer's Disease (AD). Therefore, Aβ-plaques in the brain may be a useful
 biomarker of the disease and its progression and [11 C]-PIB may be a useful tool to detect
 these plaques in the human living brain with PET.

 [11 C ]-PIB is an investigational positron emitting radiopharmaceutical (PER) not yet
 marketed in Canada. The ligand will be manufactured at CAMH PET centre. PET imaging will be
 performed using [11 C] PIB at CAMH PET Centre with PET/CT-Discovery MI scanner using the
 standardized acquisition protocol.

 The PET imaging protocol begins with a low dose CT scan (less than 0.05 mSv) for attenuation
 correction. Immediately following this acquisition, a bolus containing approximately 10 ± 1
 mCi of [11 C]-PIB is administered by IV injection, followed by 90 minutes acquisition.
 Acquisition and reconstruction of PET images are done according to the standard PET Centre
 Imaging Protocols.

 Phone Check Ups: For safety measures the participants will be contacted by phone to discuss
 any possible adverse event and general well-being two times during the course of the study:

 -  24-72 hours after the PET scan

 -  30 days (+/- 7 days) after PET Scan and/or the last study procedure
General Inclusion Criteria (All Subgroups)

 Participants must meet each of the following criteria for enrolment into the study:

 1. Written informed consent obtained and documented

 2. Male or post-menopausal female (minimum of one year since the last menstrual period)

 3. 50-90 years of age

 4. Self-reported proficiency in speaking and understanding spoken English questions

 5. ≥8 years education

 6. Capable of cooperating for the duration of the study procedures and assessments

 7. Willing to undergo study procedures and remain unaware of the results (unless there
 are findings that are of clinical significance and would require further action, in
 the opinion of the study physician)

 8. Sufficient vision to participate in cognitive testing (corrected near visual acuity of
 Snellen 20/70 in at least one eye) and eye-tracking (able to identify symbols and
 stimuli presented on a computer screen in front of them)

 9. Sufficient corrected hearing to participate in cognitive testing

 10. Good venous access for phlebotomy to be performed

 11. Able to walk, with or without an assistive aid (e.g., cane, walker)

 Subgroup-Specific Inclusion Criteria

 Cognitively Normal Controls

 1. Cognitively normal and functionally independent in pre-screening history

 2. Within normal limits on the TorCA (formally known as Behavioural Neurology Assessment
 - Revised (BNA-R)

 3. Within normal limits on the study neuropsychological battery

 Mild Cognitive Impairment (MCI)

 1. Meets the National Institute on Aging-Alzheimer's Association criteria for single or
 multi-domain amnestic MCI

 2. Impairment of episodic memory plus or minus other cognitive domains on the TorCA

 3. Montreal Cognitive Assessment (MoCA) score ≥18

 4. Mini-Mental State Examination (MMSE) > 20

 5. In the opinion of the investigator if required: reliable and capable partner who has
 regular interaction with them, can provide a collateral history, can assist in
 compliance with study procedures, and who is willing to act as the Study Partner
 (provide written informed consent) and remain unaware of the results

 Alzheimer's Disease (AD)

 1. Meets the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical
 criteria for probable or possible AD dementia

 2. Mild early AD stage, as defined by MMSE score ≥18, Atypical cases with a MoCA ≥ 14
 will also be allowed.

 3. Impairment in two or more cognitive domains on the TorCA

 4. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 Lewy Body Disease (LBD) Spectrum PD-MCI

 1. Meets the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's
 Disease

 2. MMSE score ≥20

 3. MoCA score ≥18

 4. Impairment in one or more cognitive domains of TorCA

 5. Hoehn & Yahr stage 1-3

 6. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 LBD-MCI

 1. Meets the criteria for Dementia with Lewy Bodies (McKeith et al, 2017 in press)but has
 preserved daily functioning

 2. MMSE score ≥20

 3. MoCA score ≥18

 4. Impairment in one or more cognitive domains on the TorCA

 5. Hoehn & Yahr stage ≤3

 6. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 Dementia with Lewy Bodies (DLB)

 1. Meets the criteria for probable or possible Dementia with Lewy Bodies (McKeith et al,
 2017 in press)

 2. MMSE score ≥14

 3. MoCA score ≤25

 4. Impairment in one or more cognitive domains on the TorCA

 5. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 PDD

 1. Meets the criteria for probable Parkinson's Disease - Dementia

 2. MMSE score ≥18

 3. MoCA score ≤25

 4. Impairment in two or more cognitive domains of TorCA

 5. Hoehn & Yahr stage ≤4

 6. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 Subcortical Vascular Cognitive Impairment (VCI)

 1. Presence of subcortical vascular disease, indicated by the following:

 i. Periventricular Fazekas score = 3, with or without subcortical lacunes or small
 cortical infarcts (<1.5 cm in longest diameter); or ii. Fazekas score ≥ 2, with 2 or
 more subcortical lacunes or small cortical infarcts (<1.5 cm in longest diameter); or
 iii. Fazekas score = 0 or 1, with 3 subcortical lacunar infarcts (<1.5 cm in
 diameter), at least 1 in each hemisphere; or

 iv. Probable or possible Cerebral Amyloid Angiopathy using the Modified Boston
 Criteria

 2. Impairment in one or more cognitive domains on the TorCA

 3. Reliable and capable partner who has regular interaction with them, can provide a
 collateral history, can assist in compliance with study procedures, and who is willing
 to act as the Study Partner (provide written informed consent) and remain unaware of
 the results

 Exclusion criteria General Exclusion Criteria (All Subgroups)

 Participants who exhibit any of the following conditions will be excluded from the study:

 1. Underlying conditions (other than the disease being studied) which in the opinion of
 the investigator may interfere with the participant's ability to participate in the
 study or may compromise study results, including but not limited to:

 1. Unstable cardiac, pulmonary, renal, hepatic, endocrine (i.e. diabetes) or
 hematologic disease

 2. Active malignancy or infectious disease

 3. Significant psychiatric illness, including life-long depressive illness

 4. History of significant learning disability

 5. Significant other neurologic disease (e.g., multiple sclerosis, Huntington's
 disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear
 palsy, seizure disorder, subdural hematoma) or cognitive complications of cancer

 6. Symptomatic stroke within the past 6 months

 7. Substance abuse within the past year or history of alcohol or drug abuse which in
 the opinion of the investigator may interfere with the participant's ability to
 comply with the study procedures

 8. History of significant head trauma or recurrent concussions requiring
 hospitalization followed by persistent neurologic defaults or known structural
 brain abnormalities

 9. Pain or sleep disorder that could interfere with cognitive testing

 10. Any disability that would limit the ability to perform study assessments

 2. Ocular conditions, including:

 a. Clinical diagnosis of glaucoma, taking eye drops for glaucoma, or previous surgery
 (including laser) for glaucoma b. Any other serious eye disease or treatment or eye
 surgery, including any history of intra-vitreal injections c. History of optic
 neuritis d. Previous retinal laser therapy (either pan-retinal, or grid/focal) for
 diabetic retinopathy e. Cupping of the optic nerve head (ONH) consistent with a
 diagnosis of glaucoma, as clinically determined by expert ophthalmological assessment
 of digital colour fundus images centered on the ONH. Specifically, one or more of the
 following (assessed as part of SD-OCT visit at Kensington Eye Institute): i. a
 cup/disc ratio of 0.7 or greater in either eye ii. a cup/disc asymmetry of more than
 0.2 iii. disc hemorrhage iv. notch f. Wet/exudative age-related macular degeneration
 (ARMD) in one or both eyes, as clinically determined by expert ophthalmological
 assessment of digital color fundus images centered on the fovea (assessed as part of
 SD-OCT visit at Kensington Eye Institute)

 3. Intra-ocular pressure greater than 22mmHg or a difference in intra-ocular pressure
 (Goldmann tonometry) greater than 5mmHg between the two eyes (assessed as part of
 SD-OCT visit at Kensington Eye Institute)

 4. Brain imaging abnormalities detected either on clinical MRI or CT prior to enrollment
 or on study MRI, including but not limited to:

 1. Evidence of infection

 2. Focal compressive mass lesions (tumours, subdural hematomas, malformations, etc.)

 5. Known hypersensitivity to Pittsburgh Compound B [11C]-PIB or any components of
 the[11C]-PIB Injection formulation

 6. Contraindications to 3T MRI, as listed in the site-specific Magnetic Resonance
 Environment Screening Questionnaire (e.g. metal implant)

 7. Unable to tolerate the MRI environment (e.g., due to physical size and/or
 claustrophobia)

 8. Currently enrolled in a disease-modifying therapeutic trial that in the opinion of the
 Principal Investigator can potentially compromise study results

 Subgroup-Specific Exclusion Criteria Cognitively Normal Controls

 1. Subjective memory complaints

 2. Brain imaging abnormalities detected either on clinical MRI or CT prior to enrollment
 or on study MRI, including but not limited to:

 1. Periventricular Fazekas score = 2.5 or 3

 2. Subcortical non-lacunar infarct or more than 1 subcortical lacunar infarct (<1.5
 cm in longest diameter)

 3. Cortical ischemic stroke Cortical or subcortical hemorrhagic stroke >1.5cm in
 diameter

 MCI, AD, and LBD Spectrum

 (1) Brain imaging abnormalities detected either on clinical MRI or CT prior to enrollment
 or on study MRI, including but not limited to:

 1. Periventricular Fazekas score = 2.5 or 3

 2. Subcortical non-lacunar infarct or more than 1 subcortical lacunar infarct (<1.5 cm
 diameter)

 3. Cortical ischemic stroke >1.5cm in longest diameter

 4. Cortical or subcortical hemorrhagic stroke >1.5cm in diameter